Phio Pharmaceuticals Corp. (PHIO) - Dilution Analysis

10-Q filing | 11.6M shares outstanding

S-3 filing: The selling stockholders are offering on a resale basis an aggregate of up to 11,763,800 shares of common stock of Phio Pharmaceuticals Corp.

10-Q filing | 5.5M shares outstanding

10-Q filing | 5.7M shares outstanding

10-Q filing | 4.8M shares outstanding

10-K filing | 4.8M shares outstanding

S-1 filing: The selling stockholders are offering on a resale basis an aggregate of up to 5,930,016 shares of common stock issuable upon exercise of warrants.

10-Q filing | 1.0M shares outstanding

10-Q filing | 0.9M shares outstanding

S-1 filing: The Selling Stockholders identified in this prospectus are offering on a resale basis up to 1,131,468 shares of Common Stock issuable upon exercise of the Warrants.

8-K filing: Stock split 1-for-9 | Outstanding: 4,591,700 → 510,188

S-3 filing: Phio Pharmaceuticals Corp. files an S-3 form to register the offering of common stock, preferred stock, and/or debt securities with a total value of up to $100,000,000 using a shelf registration process.

S-1 filing: Phio Pharmaceuticals Corp. files an S-1 form to register the offering of common stock, preferred stock, debt securities, warrants, and/or units with a total value of up to $100,000,000.

10-Q filing | 4.6M shares outstanding

10-K filing | 4.6M shares outstanding

S-1 filing: This S-1 filing relates to the resale of up to 4,420,273 shares of Common Stock issuable upon exercise of warrants by selling stockholders; the company will not receive any proceeds from the sale of these shares, except for the warrant exercise price.

10-Q filing | 2.4M shares outstanding

10-Q filing | 2.2M shares outstanding

S-1 filing: This is an S-1 filing for Phio Pharmaceuticals Corp., a clinical stage biotechnology company, related to a registered direct offering and a concurrent private placement for shares of common stock and warrants.

10-Q filing | 1.5M shares outstanding

S-1 filing: This S-1 filing describes a registered direct offering of common stock and warrants, along with information about the company's INTASYL technology platform and clinical trials for its drug candidates PH-762 and PH-894.

10-K filing | 1.1M shares outstanding

8-K filing: Stock split 1-for-12 | Outstanding: 13,662,857 → 1,100,000

10-Q filing | 13.7M shares outstanding

10-Q filing | 13.7M shares outstanding

10-Q filing | 13.6M shares outstanding

10-K filing | 13.5M shares outstanding

10-Q filing | 13.5M shares outstanding

10-Q filing | 13.5M shares outstanding

10-Q filing | 13.5M shares outstanding

S-3 filing: Phio Pharmaceuticals is filing an S-3 to register an indeterminate number of shares of common stock, preferred stock, debt securities, warrants and/or units with a total offering price not to exceed $100,000,000.

10-K filing | 13.5M shares outstanding

8-K filing: Phio Pharmaceuticals Corp. completed an offering of 2,246,784 shares of common stock at a price of $3.42 per share, resulting in net proceeds of approximately $6.9 million. ($7.68M proceeds)

S-3/A filing: This is an S-3/A filing to register additional securities for an offering, with the registrant amending the registration statement to delay its effective date.

S-3 filing: The Selling Stockholders are offering on a resale basis an aggregate of 8,323,694 shares of Common Stock.

8-K filing: Phio Pharmaceuticals Corp. closed a private placement on January 25, 2021, issuing 4,420,863 shares of common stock, 140,065 pre-funded warrants exercisable for 140,065 shares, and 3,420,696 common warrants exercisable for 3,420,696 shares, resulting in gross proceeds of approximately $14.0 million before deducting fees and expenses. ($13.99M proceeds)

10-Q filing | 5.8M shares outstanding

10-Q filing | 5.8M shares outstanding

S-1 filing: This S-1 filing relates to the potential resale of common stock issuable upon the exercise of warrants by selling stockholders, with Phio Pharmaceuticals not receiving proceeds except for the warrant exercise price.

S-1/A filing: Selling stockholders are offering on a resale basis an aggregate of 1,841,544 shares of common stock, including shares issuable upon the exercise of outstanding warrants.

S-1 filing: The selling stockholders are offering on a resale basis an aggregate of 1,841,544 shares of common stock, 1,713,064 shares of which are issuable upon the exercise of outstanding warrants purchased pursuant to a securities purchase agreement dated March 31, 2020, as well as 128,480 shares of which are issuable upon the exercise of Warrants issued to the Company's financial advisor in connection with the Purchase Agreement.

10-Q filing | 4.6M shares outstanding

8-K filing: Phio Pharmaceuticals Corp. completed an offering and private placement on April 2, 2020, selling 1,713,064 shares of common stock at $2.21 per share, along with warrants to purchase up to 1,713,064 shares at an exercise price of $2.21 per share, resulting in net proceeds of approximately $3.5 million. ($4.0M proceeds)

10-K filing | 2.9M shares outstanding

8-K filing: Phio Pharmaceuticals Corp. completed a public offering of 993,633 Units and 1,006,367 Pre-Funded Units at $4.00 and $3.999 per unit, respectively, for net proceeds of approximately $7.0 million.

S-1/A filing: The filing is an S-1/A filing, where the company is offering up to 1,086,956 units consisting of one share of common stock and one warrant. They are also offering pre-funded units, where each pre-funded unit consists of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock.

8-K filing: Phio Pharmaceuticals Corp. completed an offering and private placement on February 6, 2020, selling 197,056 shares of common stock at $8.705 per share and warrants to purchase up to 197,056 shares at $0.125 per warrant share, resulting in net proceeds of approximately $1.4 million.

S-1/A filing: The company is offering up to 955,566 units, each consisting of one share of common stock and one warrant, and pre-funded units, each consisting of one pre-funded warrant and one warrant.